Anebulo Pharmaceuticals (ANEB) Shares Outstanding (2020 - 2025)
Anebulo Pharmaceuticals (ANEB) posted quarterly Shares Outstanding (Entity) of $41.1 million for Q4 2025, up 49.86% year-over-year from $27.4 million in Q4 2024, and little changed quarter-over-quarter from $41.1 million in Q3 2025.
Anebulo Pharmaceuticals (ANEB) Shares Outstanding (2020 - 2025) Analysis & Trends
Anebulo Pharmaceuticals (ANEB) has reported Shares Outstanding (Entity) for 6 consecutive years, with $41.1 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Shares Outstanding (Entity) rose 49.86% year-over-year to $41.1 million; the TTM figure through Dec 2025 stood at $41.1 million (up 49.86% YoY), while the FY2025 annual figure was $33.8 million, up 30.41% from the prior year.
- Shares Outstanding (Entity) was little changed at $41.1 million in Q4 2025 per ANEB's latest filing, from $41.1 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $41.1 million in Q1 2025 and bottomed at $13.0 million in Q1 2021.
- Historically, Shares Outstanding (Entity) has averaged $26.8 million across 5 years, with a median of $25.6 million in 2022.
- Annual changes were most pronounced in 2021 — Shares Outstanding (Entity) jumped 79.82% — and 2023, when it changed 0.0%.
- Anebulo Pharmaceuticals' Shares Outstanding (Entity) stood at $23.3 million in 2021, then gained by 9.8% to $25.6 million in 2022, then advanced by 1.17% to $25.9 million in 2023, then grew by 5.72% to $27.4 million in 2024, then jumped by 49.86% to $41.1 million in 2025.
- Business Quant data shows ANEB's Shares Outstanding (Entity) at $41.1 million in Q4 2025, $41.1 million in Q3 2025, and $33.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Anebulo Pharmaceuticals | 16.43 Mn | 16.43 Mn | - | 41.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 41.08 Mn |
| Sep 30, 2025 | 41.08 Mn |
| Jun 30, 2025 | 33.82 Mn |
| Mar 31, 2025 | 41.08 Mn |
| Dec 31, 2024 | 27.42 Mn |
| Sep 30, 2024 | 25.93 Mn |
| Jun 30, 2024 | 25.82 Mn |
| Mar 31, 2024 | 25.93 Mn |
| Dec 31, 2023 | 25.79 Mn |
| Sep 30, 2023 | 25.63 Mn |
| Jun 30, 2023 | 25.07 Mn |
| Mar 31, 2023 | 25.63 Mn |
| Dec 31, 2022 | 25.63 Mn |
| Sep 30, 2022 | 23.42 Mn |
| Jun 30, 2022 | 23.34 Mn |
| Mar 31, 2022 | 23.34 Mn |
| Dec 31, 2021 | 23.34 Mn |
| Sep 30, 2021 | 23.34 Mn |
| Jun 30, 2021 | 13.61 Mn |
| Mar 31, 2021 | 12.98 Mn |